Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
- Registration Number
- NCT00080327
- Brief Summary
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 370
Inclusion Criteria
- Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 4 Placebo - 1 Aripiprazole - 2 Aripiprazole - 3 Aripiprazole -
- Primary Outcome Measures
Name Time Method Change at endpoint in schizophrenia rating scale
- Secondary Outcome Measures
Name Time Method Clinical Global Improvement scale at endpoint and time to response
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of aripiprazole's action on dopamine and serotonin receptors in acute schizophrenia?
How does aripiprazole compare to other atypical antipsychotics like risperidone in treating acute schizophrenia symptoms?
Which biomarkers correlate with aripiprazole response in patients with acute schizophrenia during phase 4 trials?
What are the most common adverse events associated with aripiprazole in phase 4 schizophrenia studies and how are they managed?
How do aripiprazole combination therapies compare to monotherapies in managing acute schizophrenia exacerbations?
Trial Locations
- Locations (1)
Bristol-Meyers Squibb Call Center
🇺🇸Wallingford, Connecticut, United States
Bristol-Meyers Squibb Call Center🇺🇸Wallingford, Connecticut, United States